Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches? by Songmao Zheng, Rodney Prell, Jennifer Sheng, Yow‐Ming Wang, Lora Hamuro

Connect to this object online.

Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology by Kinjal Sanghavi, Pradeep Vuppala, Vijay Ivaturi, Lora Hamuro, Amit Roy, Satyendra Suryawanshi

Connect to this object online.

Pediatric model‐based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma by Shengnan Du, Yue Zhao, Zheyi Hu, Sihang Liu, Amit Roy, Jun Shen, Li Zhu, Lora Hamuro

Connect to this object online.

Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body‐size effect by Zheyi Hu, Sihang Liu, Yue Zhao, Shengnan Du, Lora Hamuro, Jun Shen, Amit Roy, Li Zhu

Connect to this object online.

Immunogenicity in Clinical Practice and Drug Development: When is it Significant? by Valentina Shakhnovich, Bernd Meibohm, Amy Rosenberg, Andrzej M. Kierzek, Rachel Hasenkamp, Ryan S. Funk, Craig J. Thalhauser, Piet H. van derGraaf, Yow‐Ming C. Wang, Lora Hamuro

Connect to this object online.